AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36064395 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaging patients and their family
Number of subjects: 29
Study 36064395 — intervention group
Group type: EXPERIMENTAL
Intervention: Creating a multidisciplinary HCP interest group dedicated to HL
Number of subjects: 29
Study 36064457 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe Hands project intervention
Number of subjects: 3553
Study 36064491 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural blood patch
Number of subjects: 643
Study 36064577 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (alloHCT)
Number of subjects: 3234
Study 36064577 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 3234
Study 36064599 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS10-NPC-GDNF (human neural progenitor cells transduced with GDNF) transplanted unilaterally into the lumbar spinal cord
Number of subjects: 18
Study 36064599 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS10-NPC-GDNF
Number of subjects: 18
Study 36064670 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV-Al (aluminium-adjuvanted reduced dose inactivated polio vaccine)
Number of subjects: 0
Study 36064689 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 255
Study 36064725 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglustat use (a glucosylceramide synthase inhibitor)
Number of subjects: 120
Study 36064725 — intervention group
Group type: EXPERIMENTAL
Intervention: NIH study duration (NIHSD)
Number of subjects: 120
Study 36064725 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizure history
Number of subjects: 120
Study 36064748 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery for treatment (GIFT) - a brief, two-session guided imagery intervention.
Number of subjects: 0
Study 36064748 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) - control group.
Number of subjects: 0
Study 36064785 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36064841 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab treatment
Number of subjects: 222
Study 36064878 — intervention group
Group type: EXPERIMENTAL
Intervention: C-terminal telopeptide of type I collagen (CTX-I)
Number of subjects: 73
Study 36064878 — intervention group
Group type: EXPERIMENTAL
Intervention: Procollagen I N-terminal peptide (PINP)
Number of subjects: 73
Study 36065356 — intervention group
Group type: EXPERIMENTAL
Intervention: TearCare
Number of subjects: 235
Study 36065356 — intervention group
Group type: COMPARATOR
Intervention: LipiFlow
Number of subjects: 235
Study 36066322 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent, trained observers measuring ER distance
Number of subjects: 1
Study 36066373 — intervention group
Group type: COMPARATOR
Intervention: Conventional chest physiotherapy (versus no physiotherapy)
Number of subjects: 974
Study 36066373 — intervention group
Group type: COMPARATOR
Intervention: OMT (versus placebo)
Number of subjects: 974
Study 36066373 — intervention group
Group type: COMPARATOR
Intervention: High-frequency chest wall oscillation (versus no physiotherapy)
Number of subjects: 974
Study 36066373 — intervention group
Group type: COMPARATOR
Intervention: Active cycle of breathing techniques (versus no physiotherapy)
Number of subjects: 974
Study 36066373 — intervention group
Group type: COMPARATOR
Intervention: Positive expiratory pressure (versus no physiotherapy)
Number of subjects: 974
Study 36066373 — intervention group
Group type: COMPARATOR
Intervention: High-frequency chest wall oscillation plus fibrobronchoscope alveolar lavage (versus fibrobronchoscope alveolar lavage alone)
Number of subjects: 974
Study 36066616 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail patients
Number of subjects: 696
Study 36066616 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail patients with dementia
Number of subjects: 696
Study 36066616 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower age
Number of subjects: 696
Study 36066616 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobility, loneliness, and weight loss
Number of subjects: 696
Study 36066616 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-frail patients
Number of subjects: 696
Study 36066618 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa (BA)
Number of subjects: 936
Study 36066618 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-informed approach for management of bleeding AEs
Number of subjects: 936
Study 36066745 — intervention group
Group type: EXPERIMENTAL
Intervention: Odevixibat treatment for 24 weeks
Number of subjects: 62
Study 36066745 — intervention group
Group type: EXPERIMENTAL
Intervention: PRUCISION ObsRO instrument
Number of subjects: 62
Study 36066745 — intervention group
Group type: EXPERIMENTAL
Intervention: ObsRO scores at week 24
Number of subjects: 62
Study 36066745 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity to change analysis
Number of subjects: 62
Study 36066903 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse 15 mg/kg/day for 3 days followed by oral prednisone 1 mg/kg/day
Number of subjects: 40
Study 36066903 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone 1 mg/kg/day alone
Number of subjects: 40
Study 36066936 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management intervention with automated tailored text messages during months 1-6 for weight loss initiation and months 7-18 for weight maintenance.
Number of subjects: 462
Study 36066936 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-assisted weight management intervention with automated tailored text messages during months 1-6 for weight loss initiation and months 7-18 for weight maintenance.
Number of subjects: 462
Study 36066958 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week transdiagnostic ICBT course (Wellbeing Course for New Moms)
Number of subjects: 63
Study 36066958 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 63
Study 36066965 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV)
Number of subjects: 0
Study 36066967 — intervention group
Group type: EXPERIMENTAL
Intervention: PARTNER-MH intervention
Number of subjects: 50
Study 36066967 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 50
Study 36067063 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab subcutaneous (DARA SC) 1800 mg every 4 weeks
Number of subjects: 192
Study 36067063 — intervention group
Group type: COMPARATOR
Intervention: Daratumumab intravenous (DARA IV)
Number of subjects: 192
Study 36067063 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab subcutaneous (DARA SC)
Number of subjects: 192
Study 36067139 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy interventions recommended by physiotherapists (education, spinal exercises, manual therapy)
Number of subjects: 300
Study 36067139 — intervention group
Group type: COMPARATOR
Intervention: Passive physiotherapy approaches prescribed by general practitioners (massage therapy, electrotherapy)
Number of subjects: 300
Study 36067139 — intervention group
Group type: COMPARATOR
Intervention: Overall agreement for diagnosis or reason of referral
Number of subjects: 300
Study 36067139 — intervention group
Group type: COMPARATOR
Intervention: Compliance with evidence-based recommendations
Number of subjects: 300
Study 36067271 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological adjustment and adaptation interventions; specific details not available
Number of subjects: 0
Study 36067410 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation training with handheld or stand optical magnifier or portable electronic magnifier
Number of subjects: 14
Study 36068495 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI (5-fluorouracil, leucovorin, oxaliplatin, and irinotecan) administered for six two-weekly cycles prior to chemoradiotherapy.
Number of subjects: 128
Study 36068503 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-positive myocarditis (group A), 12 patients (25.5%)
Number of subjects: 51
Study 36068503 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-negative myocarditis (group B), 35 patients (74.5%)
Number of subjects: 51
Study 36068503 — intervention group
Group type: EXPERIMENTAL
Intervention: Serological analysis for cardiotropic viruses
Number of subjects: 51
Study 36068611 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case management
Number of subjects: 0
Study 36068611 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote blood pressure (BP) monitoring
Number of subjects: 0
Study 36068611 — intervention group
Group type: EXPERIMENTAL
Intervention: Social determinants of health (SDoH) support
Number of subjects: 0
Study 36068647 — intervention group
Group type: EXPERIMENTAL
Intervention: quintuply-fortified salt with iron in the form of encapsulated ferrous fumarate, zinc, vitamin B12, folic acid, and iodine (eFF-Q5S)
Number of subjects: 1248
Study 36068647 — intervention group
Group type: EXPERIMENTAL
Intervention: quintuply-fortified salt with iron in the form of ferric pyrophosphate plus EDTA, zinc, vitamin B12, folic acid, and iodine (FePP-Q5S)
Number of subjects: 1248
Study 36068647 — intervention group
Group type: COMPARATOR
Intervention: iodized salt (IS)
Number of subjects: 1248
Study 36068647 — intervention group
Group type: EXPERIMENTAL
Intervention: quintuply-fortified salt (MFS)
Number of subjects: 1248
Study 36068858 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine treatment for MDD (6 months)
Number of subjects: 184
Study 36068950 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispecific LV20.19 CAR T-cell therapy at a target dose of 2.5 × 10^6 cells/kg
Number of subjects: 0
Study 36069000 — intervention group
Group type: EXPERIMENTAL
Intervention: Original QOC EOL subscale
Number of subjects: 56
Study 36069000 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted QOC EOL subscale
Number of subjects: 56
Study 36069141 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal respiratory viral infection
Number of subjects: 3931
Study 36069141 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory syncytial virus (RSV)
Number of subjects: 3931
Study 36069336 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance enterocolonography (MREC)
Number of subjects: 153
Study 36069336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pan-enteric capsule endoscopy (CE)
Number of subjects: 153
Study 36069336 — intervention group
Group type: COMPARATOR
Intervention: Ileocolonoscopy (IC)
Number of subjects: 153
Study 36069495 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH (150 IU daily)
Number of subjects: 366
Study 36069781 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted REBOOT intervention
Number of subjects: 10
Study 36069838 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 273
Study 36069838 — intervention group
Group type: EXPERIMENTAL
Intervention: Light physical activity (LPA)
Number of subjects: 273
Study 36069838 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in movement behaviors
Number of subjects: 273
Study 36070087 — intervention group
Group type: EXPERIMENTAL
Intervention: Children born VLBW
Number of subjects: 77
Study 36070087 — intervention group
Group type: EXPERIMENTAL
Intervention: Children born VLBW classified as vulnerable
Number of subjects: 77
Study 36070087 — intervention group
Group type: EXPERIMENTAL
Intervention: Apgar <7
Number of subjects: 77
Study 36070134 — intervention group
Group type: COMPARATOR
Intervention: Mobility strategies (various types of exercise and muscle stimulation) in-hospital
Number of subjects: 4059
Study 36070134 — intervention group
Group type: COMPARATOR
Intervention: Gait, balance and functional training in-hospital
Number of subjects: 4059
Study 36070134 — intervention group
Group type: COMPARATOR
Intervention: Mobility strategies (various types of exercise) post-hospital
Number of subjects: 4059
Study 36070134 — intervention group
Group type: COMPARATOR
Intervention: Training involving gait, balance and functional exercise post-hospital
Number of subjects: 4059
Study 36070134 — intervention group
Group type: COMPARATOR
Intervention: Resistance or strength exercise post-hospital
Number of subjects: 4059
Study 36070134 — intervention group
Group type: COMPARATOR
Intervention: Multiple intervention components post-hospital
Number of subjects: 4059
Study 36070176 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent inactivated split-virion influenza vaccine (QIV; Vaxigrip Tetra)
Number of subjects: 663
Study 36070539 — intervention group
Group type: EXPERIMENTAL
Intervention: UCPVax (0.25 mg, 0.5 mg, and 1 mg)
Number of subjects: 59
Study 36070540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pafolacianine (0.025 mg/kg IV), given ≥ 1 hour before intraoperative near-infrared imaging
Number of subjects: 150
Study 36070558 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT with LDR brachytherapy boost
Number of subjects: 0
Study 36070558 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT with a simultaneous integrated boost
Number of subjects: 0
Study 36070558 — intervention group
Group type: COMPARATOR
Intervention: EBRT alone
Number of subjects: 0
Study 36070558 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy
Number of subjects: 0
Study 36071122 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise intervention including aerobic and strength training
Number of subjects: 13
Study 36071122 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise intervention
Number of subjects: 13
Study 36071311 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifocal strategy
Number of subjects: 194
Study 36071311 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractive bifocal strategy
Number of subjects: 194
Study 36071311 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended strategy
Number of subjects: 194
Study 36071311 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffractive bifocal strategy
Number of subjects: 194
Study 36071311 — intervention group
Group type: EXPERIMENTAL
Intervention: EDOF strategy
Number of subjects: 194
Study 36071311 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovision strategy
Number of subjects: 194
Study 36071311 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofocal strategy
Number of subjects: 194
Study 36071311 — intervention group
Group type: COMPARATOR
Intervention: Trifocal strategy compared to refractive bifocal strategy
Number of subjects: 194
Study 36071389 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Pillars™ Practice Transformation Program
Number of subjects: 365
Study 36071439 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital at Home (HaH-HA)
Number of subjects: 0
Study 36071439 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospitalization (UC)
Number of subjects: 0
Study 36071461 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption
Number of subjects: 42
Study 36071461 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 42
Study 36072606 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled human malaria infection (CHMI) with homologous blood-stage parasites
Number of subjects: 0
Study 36072606 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 36072887 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 105
Study 36072887 — intervention group
Group type: EXPERIMENTAL
Intervention: A allele carriers
Number of subjects: 105
Study 36072887 — intervention group
Group type: EXPERIMENTAL
Intervention: FTO genotype
Number of subjects: 105
Study 36072945 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of ART
Number of subjects: 0
Study 36072945 — intervention group
Group type: COMPARATOR
Intervention: Analytic treatment interruption (ATI)
Number of subjects: 0
Study 36072994 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab (0.3, 0.6, or 1.0 mg/kg subcutaneous injection every 4 weeks, titrated at Week 12)
Number of subjects: 0
Study 36072994 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab
Number of subjects: 0
Study 36073247 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase beta treatment
Number of subjects: 0
Study 36073629 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36073641 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ACS and OSA
Number of subjects: 1174
Study 36073641 — intervention group
Group type: COMPARATOR
Intervention: Patients without OSA
Number of subjects: 1174
Study 36073641 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 1174
Study 36073646 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic group (AFEQT score ≤80)
Number of subjects: 1515
Study 36073646 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic group (AFEQT score >80)
Number of subjects: 1515
Study 36073645 — intervention group
Group type: EXPERIMENTAL
Intervention: LA emptying fraction measured by transthoracic echocardiography
Number of subjects: 1866
Study 36073645 — intervention group
Group type: EXPERIMENTAL
Intervention: Indexed LA volumes
Number of subjects: 1866
Study 36073645 — intervention group
Group type: EXPERIMENTAL
Intervention: LA emptying fraction and indexed LA volumes
Number of subjects: 1866
Study 36073648 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum drug measurements
Number of subjects: 19
Study 36073648 — intervention group
Group type: COMPARATOR
Intervention: Directly observed therapy
Number of subjects: 19
Study 36074028 — intervention group
Group type: EXPERIMENTAL
Intervention: School of Health for Older People intervention
Number of subjects: 135
Study 36074028 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 135
Study 36074157 — intervention group
Group type: EXPERIMENTAL
Intervention: High adrenal uptake
Number of subjects: 15
Study 36074545 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes prevention intervention via smartphone app and group support
Number of subjects: 60
Study 36074545 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 36074546 — intervention group
Group type: EXPERIMENTAL
Intervention: BEST4Baby app used by peer counselors (PCs) during home visits
Number of subjects: 22
Study 36074546 — intervention group
Group type: EXPERIMENTAL
Intervention: BEST4Baby app
Number of subjects: 22
Study 36074550 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT)
Number of subjects: 192
Study 36074550 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Affective Imagery (PAI)
Number of subjects: 192
Study 36074550 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning
Number of subjects: 192
Study 36074550 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (5 times/week)
Number of subjects: 192
Study 36074550 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (1 time/week)
Number of subjects: 192
Study 36074550 — intervention group
Group type: COMPARATOR
Intervention: Recent thinking (control for EFT)
Number of subjects: 192
Study 36074550 — intervention group
Group type: COMPARATOR
Intervention: Neutral imagery (control for PAI)
Number of subjects: 192
Study 36074550 — intervention group
Group type: COMPARATOR
Intervention: No planning (control for planning)
Number of subjects: 192
Study 36074551 — intervention group
Group type: EXPERIMENTAL
Intervention: Tough Talks (TT) app, an mHealth intervention using AI-facilitated role-playing scenarios
Number of subjects: 8
Study 36074662 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 0
Study 36074662 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 0
Study 36074716 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed-Up-and-Go (TUG)
Number of subjects: 2544
Study 36074716 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast gait speed (GS)
Number of subjects: 2544
Study 36074716 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-oriented mobility assessment (POMA)
Number of subjects: 2544
Study 36074716 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extension strength (KES)
Number of subjects: 2544
Study 36074992 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune tolerance induction (ITI) with the same FVIII product (a single source of recombinant, human full-length FVIII) used in HIPS until successful tolerance, declared failure, or a maximum of 2 years after HIPS-ITI enrollment.
Number of subjects: 5
Study 36075062 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGIC algorithm (Malignancy Assessment using Gene Identification in Captured Cells)
Number of subjects: 183
Study 36075062 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGIC algorithm
Number of subjects: 183
Study 36075062 — intervention group
Group type: COMPARATOR
Intervention: Individual genes
Number of subjects: 183
Study 36075062 — intervention group
Group type: COMPARATOR
Intervention: Multivariate model combining 14 different genes
Number of subjects: 183
Study 36075183 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib (6 weeks)
Number of subjects: 2
Study 36075183 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib (12 weeks)
Number of subjects: 2
Study 36075299 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiosurgery (hypo-RS) schedule of 25 Gy in 5 fractions
Number of subjects: 178
Study 36075495 — intervention group
Group type: EXPERIMENTAL
Intervention: Clade efg infections
Number of subjects: 274
Study 36075501 — intervention group
Group type: EXPERIMENTAL
Intervention: PAN-PROMISE
Number of subjects: 679
Study 36075501 — intervention group
Group type: COMPARATOR
Intervention: CC criteria for PEP
Number of subjects: 679
Study 36075532 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadless ventricular pacemaker with accelerometer-based algorithms (Micra AV)
Number of subjects: 152
Study 36075532 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadless ventricular pacemaker with programming optimization
Number of subjects: 152
Study 36075532 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadless ventricular pacemaker (Micra AV)
Number of subjects: 152
Study 36075560 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.56 GBq resin yttrium-90
Number of subjects: 30
Study 36075560 — intervention group
Group type: EXPERIMENTAL
Intervention: Scout Dose Resin Yttrium-90 Microspheres
Number of subjects: 30
Study 36075585 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related hearing loss (ARHL) severity
Number of subjects: 429